Literature DB >> 15833284

Characterization by liquid chromatography combined with mass spectrometry of monoclonal anti-IGF-1 receptor antibodies produced in CHO and NS0 cells.

Alain Beck1, Marie-Claire Bussat, Nathalie Zorn, Virginie Robillard, Christine Klinguer-Hamour, Stéphane Chenu, Liliane Goetsch, Nathalie Corvaïa, Alain Van Dorsselaer, Jean-François Haeuw.   

Abstract

7H2HM is a new humanized recombinant monoclonal antibody (MAb) directed against insulin-like growth factor-1 receptor and produced in CHO cells. Homogeneity of intact antibody, reduced light and heavy chains, Fab and Fc fragments were investigated by analytical methods based on mass (SDS-PAGE, SEC), charge (IEF, C-IEX) and hydrophobicity differences (RP-HPLC, HIC) and compared side-by-side with A2CHM, produced in NS0 cells. Primary structures and disulfide bridge pairing were analyzed by microsequencing (Edman degradation), mass spectrometry (MALDI-TOF, ES-TOF) and peptide mapping after enzymatic digestion (Trypsin, endoprotease Lys-C, papain). The light chains demonstrated the expected sequences. The heavy chains yielded post-translational modifications previously reported for other recombinant humanized or human IgG1 such as N-terminal pyroglutamic acid, C-terminal lysine clipping and N-glycosylation for asparagine 297. More surprisingly, two-thirds of the 7H2HM heavy chains were shown to contain an additional 24-amino-acid sequence, corresponding to the translation of an intron located between the variable and the constant domains. Taken together these data suggest that 7H2HM is a mixture of three families of antibodies corresponding (i) to the expected structure (17%; 14,9297 Da; 1330 amino acids), (ii) a variant with a translated intron in one heavy chains (33%; 15,2878 Da; 1354 amino acids) and (iii) a variant with translated introns in two heavy chains (50%; 15,4459 Da; 1378 amino acids), respectively. RP-HPLC is not a commonly used chromatographic method to assess purity of monoclonal antibodies but unlike to SEC and SDS-PAGE, was able to show and to quantify the family of structures present in 7H2HM, which were also identified by peptide mapping, mass spectrometry and microsequencing.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15833284     DOI: 10.1016/j.jchromb.2004.06.052

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  23 in total

1.  Rapid comparison of a candidate biosimilar to an innovator monoclonal antibody with advanced liquid chromatography and mass spectrometry technologies.

Authors:  Hongwei Xie; Asish Chakraborty; Joomi Ahn; Ying Qing Yu; Deepalakshmi P Dakshinamoorthy; Martin Gilar; Weibin Chen; St John Skilton; Jeffery R Mazzeo
Journal:  MAbs       Date:  2010-07-01       Impact factor: 5.857

2.  Mass measurement and top-down HPLC/MS analysis of intact monoclonal antibodies on a hybrid linear quadrupole ion trap-Orbitrap mass spectrometer.

Authors:  Pavel V Bondarenko; Tonya P Second; Vlad Zabrouskov; Alexander A Makarov; Zhongqi Zhang
Journal:  J Am Soc Mass Spectrom       Date:  2009-03-28       Impact factor: 3.109

3.  European Medicines Agency workshop on biosimilar monoclonal antibodies: July 2, 2009, London, UK.

Authors:  Janice M Reichert; Alain Beck; Harish Iyer
Journal:  MAbs       Date:  2009-09-25       Impact factor: 5.857

4.  Electrospray ionization quadrupole ion-mobility time-of-flight mass spectrometry as a tool to distinguish the lot-to-lot heterogeneity in N-glycosylation profile of the therapeutic monoclonal antibody trastuzumab.

Authors:  Carola W N Damen; Weibin Chen; Asish B Chakraborty; Mike van Oosterhout; Jeffrey R Mazzeo; John C Gebler; Jan H M Schellens; Hilde Rosing; Jos H Beijnen
Journal:  J Am Soc Mass Spectrom       Date:  2009-08-07       Impact factor: 3.109

5.  Determination of primary structure and microheterogeneity of a beta-amyloid plaque-specific antibody using high-performance LC-tandem mass spectrometry.

Authors:  Irina Perdivara; Leesa Deterding; Adrian Moise; Kenneth B Tomer; Michael Przybylski
Journal:  Anal Bioanal Chem       Date:  2008-03-28       Impact factor: 4.142

6.  Analysis of reduced monoclonal antibodies using size exclusion chromatography coupled with mass spectrometry.

Authors:  Hongcheng Liu; Georgeen Gaza-Bulseco; Chris Chumsae
Journal:  J Am Soc Mass Spectrom       Date:  2009-08-28       Impact factor: 3.109

7.  5th European Antibody Congress 2009: November 30–December 2, 2009, Geneva, Switzerland.

Authors:  Alain Beck; Janice M Reichert; Thierry Wurch
Journal:  MAbs       Date:  2010 Mar-Apr       Impact factor: 5.857

8.  Monoclonal antibodies biosimilarity assessment using transient isotachophoresis capillary zone electrophoresis-tandem mass spectrometry.

Authors:  Rabah Gahoual; Michaël Biacchi; Johana Chicher; Lauriane Kuhn; Philippe Hammann; Alain Beck; Emmanuelle Leize-Wagner; Yannis N François
Journal:  MAbs       Date:  2014       Impact factor: 5.857

9.  Monitoring therapeutic monoclonal antibodies in brain tumor.

Authors:  Rima Ait-Belkacem; Caroline Berenguer; Claude Villard; L'Houcine Ouafik; Dominique Figarella-Branger; Alain Beck; Olivier Chinot; Daniel Lafitte
Journal:  MAbs       Date:  2014       Impact factor: 5.857

Review 10.  Analytical and Functional Aspects of Antibody Sialylation.

Authors:  Johannes Stadlmann; Martin Pabst; Friedrich Altmann
Journal:  J Clin Immunol       Date:  2010-05       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.